Cegedim: Pharmaceutical segment in Romania loses 4 per cent in Q1 and reaches 669 million Euro
The pharmaceutical products sales in Romania, reflected in the distribution price decreased by four per cent in Q1 this year compared to the same interval of 2013 and reached a total value of 668.8 million Euro, under expectations, according to Cegedim data.
Petru Craciun, general manager of Cegedim states that the slightly warmer winter is accountable for the results. For 2014, in the context of a yet not updated subsidized medicine product list, the estimates take into account a decrease from 2.7 per cent to -0.3 per cent in local currency for the market. The decrease in lei for the Q1 was estimated at 1.5 per cent, to 3 billion lei.
In Q1, the pharmaceutical retail segment for Rx products reached 471.7 million Euro (2.12 billion lei), 2.2 per cent less while OTCs accounted for 109 million Euro (490 million lei), increased value of 2.4 per cent. The overall retail decreased in Q1 with 3.9 per cent and reached 580.6 million Euro, while other distribution channels such as hospitals increased with 4.9 per cent to 88.2 million Euro.
The company ranking for this market is led by Servier with 673.3 million lei and increase of 5.8 per cent, Pfizer with 600.1 million lei and 5.1 per cent increase, GlaxoSmithKline (510,3 million lei and 4,4 per cent), Ranbaxy (464,6 million lei and 4 per cent), Merck&Co (450,5 million lei and 3,8 per cent), AstraZeneca (440,3 million lei and 3,8 per cent) and Krka (316 million lei and 2,7 per cent).
They are followed by Johnson&Johnson, Antibiotice, Abbvie, Teva, Menarini, Bayer, Bristol Myers Squibb, Alvogen, Actavis and Eli Lilly, with market shares between 2.5 per cent and 1.6 per cent.